Tao Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tao Qin has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Bo Song
Department of Pathology and Forensics, Dalian Medical University, Dalian 116044, China
1 shared publication - Chunqing Ai
SKL of Marine Food Processing & Safety Control, National Engineering Research Center of Seafood, Collaborative Innovation Center of Seafood Deep Processing, National & Local Joint Engineering Laboratory for Marine Bioactive Polysaccharide Development and Application, Liaoning Key Laboratory of Food Nutrition and Health, School of Food Science and Technology, Dalian Polytechnic University, Dalian 116034, China
1 shared publication - Dapeng Wu
Department of Oncology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China
1 shared publication Dongjie Liu
Department of Second Recuperation, Dalian Rehabilitation Recuperation Center of Joint Logistics Support Force of PLA, Dalian, China
1 shared publicationHaining Wang
Department of Oncology, Qingdao, China
1 shared publicationHuixian Qiu
Qingdao Medical College, Qingdao University
1 shared publication
Latest Publications
- Open Access
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1845691
Association of intratumoral CD68+CD163+ M2-like macrophages with survival in metastatic colorectal cancer treated with chemotherapy plus bevacizumab
Background: Metastatic colorectal cancer (mCRC) is a common and highly lethal gastrointestinal malignancy. Although chemotherapy combined with bevacizumab is a standard first-line treatment, post-treatment resistance severely limits patients’ long-term survival. While the remodeling of tumor-associated macrophages (TAMs) is closely related to targeted therapy resistance, the specific impact of TAMs and their programmed death-ligand 1 (PD-L1) expression on post-treatment resistance and prognosis remains unclear. This study aimed to investigate the spatial distribution and immunophenotypic characteristics of CD68 + CD163 + M2-like TAMs and their association with post-treatment resistance and survival. Methods: We retrospectively analyzed clinical data and tumor tissues from 44 patients with mCRC who received first-line chemotherapy plus bevacizumab and were categorized into resistant and non-resistant groups. Multiplex immunofluorescence and digital image-based quantitative analysis were used to evaluate macrophage markers (CD68 and CD163) and PD-L1 expression in the whole tumor section, tumor areas, and stromal areas. Results: Compared with the non-resistant group, resistant patients showed significantly increased proportions and densities of CD68 + CD163 + M2-like TAMs and CD68 + CD163 + PD-L1 + M2-like TAMs in the tumor areas (all p < 0.05). The infiltration levels of these macrophage subsets were significantly associated with post-treatment resistance, but not with conventional clinicopathological features such as sex, age, or tumor stage. Survival analysis showed that a high density of intratumoral CD68 + CD163 + M2-like TAMs was significantly associated with shorter overall survival (OS) (p < 0.05) and showed a trend toward shorter progression-free survival (PFS) (p = 0.06). Multivariate Cox regression further demonstrated that dense intratumoral infiltration of CD68 + CD163 + M2-like TAMs was independently associated with unfavorable OS and PFS. Conclusion: In mCRC patients exhibiting resistance to chemotherapy combined with bevacizumab, the infiltration of intratumoral CD68 + CD163 + M2-like TAMs and their PD-L1-expressing subsets is significantly elevated. Notably, a high density of intratumoral CD68 + CD163 + M2-like TAMs serves as an independent poor prognostic marker for both PFS and OS. These findings demonstrate that the spatial enrichment of CD68 + CD163 + M2-like TAMs within the tumor microenvironment is closely associated with treatment resistance, suggesting that macrophage-targeted interventions may represent a potential strategy to enhance the efficacy of anti-tumor therapies in mCRC.
- 17 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1845691
Open AccessAssociation of intratumoral CD68+CD163+ M2-like macrophages with survival in metastatic colorectal cancer treated with chemotherapy plus bevacizumab
Background: Metastatic colorectal cancer (mCRC) is a common and highly lethal gastrointestinal malignancy. Although chemotherapy combined with bevacizumab is a standard first-line treatment, post-treatment resistance severely limits patients’ long-term survival. While the remodeling of tumor-associated macrophages (TAMs) is closely related to targeted therapy resistance, the specific impact of TAMs and their programmed death-ligand 1 (PD-L1) expression on post-treatment resistance and prognosis remains unclear. This study aimed to investigate the spatial distribution and immunophenotypic characteristics of CD68 + CD163 + M2-like TAMs and their association with post-treatment resistance and survival. Methods: We retrospectively analyzed clinical data and tumor tissues from 44 patients with mCRC who received first-line chemotherapy plus bevacizumab and were categorized into resistant and non-resistant groups. Multiplex immunofluorescence and digital image-based quantitative analysis were used to evaluate macrophage markers (CD68 and CD163) and PD-L1 expression in the whole tumor section, tumor areas, and stromal areas. Results: Compared with the non-resistant group, resistant patients showed significantly increased proportions and densities of CD68 + CD163 + M2-like TAMs and CD68 + CD163 + PD-L1 + M2-like TAMs in the tumor areas (all p < 0.05). The infiltration levels of these macrophage subsets were significantly associated with post-treatment resistance, but not with conventional clinicopathological features such as sex, age, or tumor stage. Survival analysis showed that a high density of intratumoral CD68 + CD163 + M2-like TAMs was significantly associated with shorter overall survival (OS) (p < 0.05) and showed a trend toward shorter progression-free survival (PFS) (p = 0.06). Multivariate Cox regression further demonstrated that dense intratumoral infiltration of CD68 + CD163 + M2-like TAMs was independently associated with unfavorable OS and PFS. Conclusion: In mCRC patients exhibiting resistance to chemotherapy combined with bevacizumab, the infiltration of intratumoral CD68 + CD163 + M2-like TAMs and their PD-L1-expressing subsets is significantly elevated. Notably, a high density of intratumoral CD68 + CD163 + M2-like TAMs serves as an independent poor prognostic marker for both PFS and OS. These findings demonstrate that the spatial enrichment of CD68 + CD163 + M2-like TAMs within the tumor microenvironment is closely associated with treatment resistance, suggesting that macrophage-targeted interventions may represent a potential strategy to enhance the efficacy of anti-tumor therapies in mCRC.
- Open Access
Bacteroides finegoldii and Parabacteroides goldsteinii Mediate Fucoidan-Induced Attenuation of Intestinal Inflammation in Mice Through Betaine- and Spermidine-Related Pathways
Fucoidan improves host health by enriching beneficial taxa such as Bacteroides and Parabacteroides, yet the underlying mechanisms remain unclear. This study validated the association between these two genera and fucoidan-mediated mitigation of intestinal inflammation in mice. Subsequently, the effects of Parabacteroides goldsteinii and Bacteroides finegoldii were evaluated in colitis mice, and the contributions of microbiota-associated metabolites spermidine and betaine were investigated in vitro. Both strains reduced IL-6 (32–36%), TNF-α (30–37%), and IL-1β (40–45%) levels and increased levels of catalase (25–35%) and glutathione peroxidase (31–45%) in the colon. Mechanically, these strains suppressed activation of the NF-κB and MAPK pathways and preserved tight junction integrity by inhibiting myosin light chain kinase activation. These effects were associated with alterations of gut microbiota, characterized by decreased Proteobacteria and increased Bacteroidota, resulting in increased betaine (45–60%) and spermidine (90–112%). In vitro, betaine and spermidine alleviated LPS-induced inflammation and oxidative damage by regulating macrophage polarization. These results suggest that Bacteroides and Parabacteroides contribute to fucoidan-induced improvement of host health through betaine- and spermidine-related pathways. Future studies should clarify the origins of key metabolites and validate their causality and translational relevance using approaches such as fecal microbiota transplantation, metabolite tracing, and human-relevant systems.
Open AccessBacteroides finegoldii and Parabacteroides goldsteinii Mediate Fucoidan-Induced Attenuation of Intestinal Inflammation in Mice Through Betaine- and Spermidine-Related Pathways
Fucoidan improves host health by enriching beneficial taxa such as Bacteroides and Parabacteroides, yet the underlying mechanisms remain unclear. This study validated the association between these two genera and fucoidan-mediated mitigation of intestinal inflammation in mice. Subsequently, the effects of Parabacteroides goldsteinii and Bacteroides finegoldii were evaluated in colitis mice, and the contributions of microbiota-associated metabolites spermidine and betaine were investigated in vitro. Both strains reduced IL-6 (32–36%), TNF-α (30–37%), and IL-1β (40–45%) levels and increased levels of catalase (25–35%) and glutathione peroxidase (31–45%) in the colon. Mechanically, these strains suppressed activation of the NF-κB and MAPK pathways and preserved tight junction integrity by inhibiting myosin light chain kinase activation. These effects were associated with alterations of gut microbiota, characterized by decreased Proteobacteria and increased Bacteroidota, resulting in increased betaine (45–60%) and spermidine (90–112%). In vitro, betaine and spermidine alleviated LPS-induced inflammation and oxidative damage by regulating macrophage polarization. These results suggest that Bacteroides and Parabacteroides contribute to fucoidan-induced improvement of host health through betaine- and spermidine-related pathways. Future studies should clarify the origins of key metabolites and validate their causality and translational relevance using approaches such as fecal microbiota transplantation, metabolite tracing, and human-relevant systems.
- Open Access
- 20 February 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-14
Unravelling the role of ubiquitin-specific proteases in breast carcinoma: insights into tumour progression and immune microenvironment modulation
Breast cancer is a prevalent malignancy worldwide, and its treatment has increasingly shifted towards precision medicine, with immunotherapy emerging as a key therapeutic strategy. Deubiquitination, an essential epigenetic modification, is regulated by deubiquitinating enzymes (DUBs) and plays a critical role in immune function and tumor progression. Ubiquitin-specific proteases (USPs), a prominent subgroup of DUBs, are involved in regulating immune cell functions, antigen processing, and T cell development in the context of breast cancer. Certain USPs also modulate the differentiation of immune cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), within the breast cancer immune microenvironment. Furthermore, several USPs influence the expression of PD-L1, thus affecting the efficacy of immune checkpoint inhibitors. The overexpression of USPs may promote immune evasion, contributing to the development of treatment resistance. This review elucidates the role of USPs in modulating the immune microenvironment and immune responses in breast cancer. Additionally, it discusses effective strategies for combining USP inhibitors with other therapeutic agents to enhance treatment outcomes. Therefore, targeting USPs presents the potential to enhance the efficacy of immunotherapy and overcome drug resistance, offering a more effective treatment strategy for breast cancer patients.
- 20 February 2025
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 23 (1) , 1-14
Open AccessUnravelling the role of ubiquitin-specific proteases in breast carcinoma: insights into tumour progression and immune microenvironment modulation
Breast cancer is a prevalent malignancy worldwide, and its treatment has increasingly shifted towards precision medicine, with immunotherapy emerging as a key therapeutic strategy. Deubiquitination, an essential epigenetic modification, is regulated by deubiquitinating enzymes (DUBs) and plays a critical role in immune function and tumor progression. Ubiquitin-specific proteases (USPs), a prominent subgroup of DUBs, are involved in regulating immune cell functions, antigen processing, and T cell development in the context of breast cancer. Certain USPs also modulate the differentiation of immune cells, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), within the breast cancer immune microenvironment. Furthermore, several USPs influence the expression of PD-L1, thus affecting the efficacy of immune checkpoint inhibitors. The overexpression of USPs may promote immune evasion, contributing to the development of treatment resistance. This review elucidates the role of USPs in modulating the immune microenvironment and immune responses in breast cancer. Additionally, it discusses effective strategies for combining USP inhibitors with other therapeutic agents to enhance treatment outcomes. Therefore, targeting USPs presents the potential to enhance the efficacy of immunotherapy and overcome drug resistance, offering a more effective treatment strategy for breast cancer patients.
- Open Access
- 13 June 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-14
PTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Background: Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies, including breast cancer (BC). However, whether the PTENP1/miR-20a/PTEN axis exists and how it functions in BC progression remains elusive. Methods: The levels of PTENP1, PTEN and miR-20a were measured by qRT-PCR. Furthermore, the breast cancer cells proliferation was further measured by CCK8 assay, colony formation assays, EDU and Ki67 staining. The migratory and invasive ability was determined by transwell assay. Flow cytometry, JC-1 and TUNEL assays were conducted to show the occurrence of apoptosis. Xenograft model was used to show the tumorigenesis of breast cancer cells. Results: We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis. Moreover, alteration of PTENP1 affects BC cell proliferation, invasion, tumorigenesis and chemoresistance to adriamycin (ADR). Bioinformatic analysis and dual-luciferase reporter gene assay predicted that PTENP1 was a direct target of miR-20a, which was clarified an alternative effect on BC aggressiveness phenotype. In addition, PTENP1 functioned as an endogenous sponge of miR-20a to regulate PTEN expression, which mediated BC cells proliferation, invasion and drug resistance via activation the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. PI3K inhibitor LY294002 or siAkt also prevented BC cells progression. Conclusion: Collectively, these data indicated that PTENP1/miR-20a/PTEN axis involved in the malignant behaviors of BC cells, illuminating the possible mechanism mediated by PTEN via PI3K/Akt pathway. Targeting PTENP1/miR-20a/PTEN may provide a potential diagnosis and treatment strategy for BC.
- 13 June 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-14
Open AccessPTENP1/miR-20a/PTEN axis contributes to breast cancer progression by regulating PTEN via PI3K/AKT pathway
Background: Long non-coding RNA PTENP1, the pseudogene of PTEN tumor suppressor, has been reported to exert its tumor suppressive function via modulation of PTEN expression in many malignancies, including breast cancer (BC). However, whether the PTENP1/miR-20a/PTEN axis exists and how it functions in BC progression remains elusive. Methods: The levels of PTENP1, PTEN and miR-20a were measured by qRT-PCR. Furthermore, the breast cancer cells proliferation was further measured by CCK8 assay, colony formation assays, EDU and Ki67 staining. The migratory and invasive ability was determined by transwell assay. Flow cytometry, JC-1 and TUNEL assays were conducted to show the occurrence of apoptosis. Xenograft model was used to show the tumorigenesis of breast cancer cells. Results: We analyzed PTENP1 and PTEN levels in clinical BC samples and cell lines, and found that PTENP1 and PTEN were confirmed and closely correlated with the malignancy of BC cell lines and poor clinical prognosis. Moreover, alteration of PTENP1 affects BC cell proliferation, invasion, tumorigenesis and chemoresistance to adriamycin (ADR). Bioinformatic analysis and dual-luciferase reporter gene assay predicted that PTENP1 was a direct target of miR-20a, which was clarified an alternative effect on BC aggressiveness phenotype. In addition, PTENP1 functioned as an endogenous sponge of miR-20a to regulate PTEN expression, which mediated BC cells proliferation, invasion and drug resistance via activation the phosphatidylinositol-3 kinase (PI3K)/AKT pathway. PI3K inhibitor LY294002 or siAkt also prevented BC cells progression. Conclusion: Collectively, these data indicated that PTENP1/miR-20a/PTEN axis involved in the malignant behaviors of BC cells, illuminating the possible mechanism mediated by PTEN via PI3K/Akt pathway. Targeting PTENP1/miR-20a/PTEN may provide a potential diagnosis and treatment strategy for BC.